

## Book Reviews

**Annual Review of Pharmacology and Toxicology. Volume 38.** Edited by Arthur K. Cho. Annual Reviews, Palo Alto, CA. 1998. vi + 581 pp. 16 × 23 cm. ISBN 0-8243-0438-1. \$60.00.

As is characteristic of the series, this volume presents short reviews on a wide range of topics, covering a variety of neurotransmitter receptors and transporters, metabolic enzymes, and other drug targets, with the focus ranging from molecular to clinical.

Several chapters address the cytochrome P450 (CYP) drug-metabolizing enzymes, either as part of an evaluation of the predictive value of *in vitro* toxicologic or metabolic models (Davila et al., Ito et al.) or as the role of a specific isoform in drug interactions (Thummel and Wilkinson). In addition to oxidation by CYP, other biotransformation mechanisms are discussed, including hydrolytic ester cleavage (Sato and Hosokawa), glutathione conjugation (Monks and Lau; Anders and Dekant), and transport across renal, hepatic, and intestinal epithelia (Zhang et al.).

Another focus is signal transduction, with discussion of the role of environmental toxins on the major transduction pathways (L. G. Costa), signal transduction by a variety of neurotransmitters and hormones (Felder and Glass; E. Costa; Miller), role of the cyclooxygenases in linking cytokines and growth factors to their biological responses (Vane et al.), and role of receptor kinases and arrestins in modulating adrenergic receptor activation (Krupnick and Benovic). Several of these chapters also cover the characterization and subclassification of receptors for cannabinoids (Felder and Glass), catecholamines (Krupnick and Benovic; Rohrer and Kobilka), GABA (E. Costa; Miller), adenosine (Miller), and acetylcholine and glutamic acid (Miller).

Clinical chapters include reviews of the role of endogenous and environmental estrogens in the induction of breast cancer (Safe), the postulated utility of growth hormone for treatment of age-related loss in bone density and lean body mass (Marcus and Hoffman), the neuronal toxicities associated with HIV infection (Lipton), and the pharmacological utility of sesquiterpene lactones derived from Mexican Asteraceae (Heinrich et al.).

The individual chapters are generally well-written and comprehensive, considering their limited length. The bibliographies are extensive, with several hundred references in some cases. References up to 1997 are included, as well as some interesting unpublished information, such as the cardiovascular and central nervous system effects of  $\alpha_2$ -adrenoceptor agonists in mice where specific  $\alpha_2$ -adrenoceptor subtypes have been disrupted (Rohrer and Kobilka).

This series of volumes continues to be useful, offering an overview of topics both related and unrelated to a particular area of expertise. Even the unrelated group can often be helpful, by providing insight into new

techniques, drug targets, and therapeutic protocols which can have broad application.

**J. Paul Hieble**

*Department of Cardiovascular Pharmacology  
SmithKline Beecham Pharmaceuticals  
King of Prussia, Pennsylvania 19406*

JM980535R

10.1021/jm980535r

**Mass Spectrometry of Biological Materials. Second Edition, Revised and Expanded.** Edited by B. S. Larsen and C. N. McEwen. Marcel Dekker, Inc., New York, NY. 1998. xiii + 469 pp. 15.5 × 23 cm. ISBN 0-8247-0157-7. \$195.00.

This volume arises in response to extensive growth in biological mass spectrometry in two interrelated areas over the last 10 years: new ionization methods and instrumentation, and in the integration of mass spectrometry into biological protocols, which has been particularly notable in the field of protein chemistry. The book deals with methods based on electrospray ionization and matrix-assisted laser desorption ionization (MALDI), both of which have opened numerous new doors in structural and analytical chemistry. Although listed as a second edition, the book is essentially new, particularly from the standpoint of topics covered. The editors' stated intent was to create an instructional volume rather than a series of reviews, a goal that has been very largely achieved. No pretense has been made (nor would it be practical) to include all areas implied by the book title, but the topics covered are all of current importance and interest.

An introductory chapter on contemporary instrumentation and ionization methods provides a welcome and practical starting point for readers not well-versed in these topics. It is followed by 16 chapters written by experts in their respective fields, emphasizing methods under recent development with examples of applications from their laboratories. Each chapter is self-contained and is grouped somewhat loosely into aspects of instrumentation (Chapters 2 and 3), target compound isolation or concentration from complex mixtures (Chapters 4–6), identification or characterization of proteins and related compounds (Chapters 7–12), measurement of noncovalent interactions and of hydrogen–deuterium exchange in studies of tertiary structure (Chapters 13 and 14), oligonucleotides and DNA (Chapters 15 and 16), and uses of mass spectral data for the screening of protein databases (Chapter 17).

Three excellent chapters stand out in providing insightful treatment of topics that are otherwise poorly covered in the literature: discussions of the roles of contemporary mass spectrometry in industrial drug discovery; a highly readable account of strategies for glycoprotein analysis; and the use of bioinformatics in protein analysis. Several chapters are similar to coverage by the same authors elsewhere in the literature but

offer the advantage of concise descriptions, with practical experimental details. These include techniques for the characterization of histocompatibility antigens and studies of noncovalent interactions in the gas phase as a mimic of solution-phase properties.

The literature covered appears to extend into early 1997. The provision of a subindex at the start of each chapter is particularly helpful, as is the inclusion of article titles in each set of references. The book is well-suited for those wishing to gain an introductory through intermediate understanding of selected topics in the applications of mass spectrometry. It would be particularly recommended to graduate or postdoctoral students, but consideration must be given to the high price of the volume.

**James A. McCloskey**

*Department of Medicinal Chemistry  
University of Utah  
Salt Lake City, Utah 84112-5820*

JM9805844

10.1021/jm9805844

**The Antidepressant Era.** By David Healy. Harvard University Press, Cambridge, MA. 1998. x + 317 pp. 16 x 24.5 cm. ISBN 0674039572. \$39.95.

Who discovered chlorpromazine? Charpentier, who synthesized it in 1950? Courvoisier, who reported distinctive effects on animal behavior and neurophysiology? Laborit, who first noticed distinctive psychotropic effects in man? Or Delay and Denicker, who clearly outlined what has now become its accepted use in psychiatry and without whose endorsement and prestige Rhône-Poulenc might never have developed it further as an antipsychotic? There have been bitter disputes over this issue, as a result of which no Nobel Prize was ever awarded for what has been the single most important breakthrough in psychiatric treatment.

Similarly, the question of who discovered imipramine can be asked. Many suggest that it was a collaborative effort. In 1954, a series of 42 tricyclic compounds (iminodibenzyl analogues) were synthesized and reported by Schindler and Haefliger (*Helv. Chim. Acta* **1954**, 37, 4) working at Geigy Pharmaceuticals in Basel, Switzerland. One of these compounds, G-22355 (which was the iminodibenzyl closest in structure to chlorpromazine), was selected for clinical trial and distributed to a wide range of clinicians for evaluation. This group included some psychiatrists, among whom was Ronald Kuhn at the Münstertal Hospital in Switzerland on Lake Konstanz. Kuhn, who is now credited by many as the "discoverer" of the antidepressant effects of imipramine (G-22355), made his discovery as a result of careful observations on depressed patients from 1955 to 1956. In February 1957, Kuhn sent a report to Geigy endorsing the drug as a potential antidepressant, and in August of that year, he published his findings in a Swiss medical journal and presented his research at the World Conference of Psychiatry, which was held in Zurich in September. Interestingly however, Kuhn was not invited to participate at the First International Congress of Neuropsychopharmacology (CINP) held in

Rome in 1958, even though there were presentations on imipramine. He was also not invited to the second and third CINP meetings.

Multiple independent discovery happens often enough in science, and the discovery of the antidepressants is no exception. Nathan Kline is generally credited with the discovery of the antidepressant effect of iproniazid. Kline, in contrast to Kuhn, was flamboyant and cosmopolitan, ready to adopt new ideas, and had considerable political savvy. Kline, at the time of his involvement with iproniazid in 1954, was an Assistant Clinical Professor of Psychiatry at Columbia University and director of the research facility at Rockland State Hospital in New York. He published the initial account of the clinical effects of iproniazid in the *Congressional Record* of 1956. However, where no one was honored for the discovery of chlorpromazine or imipramine, Kline was awarded the Lasker Prize in 1957 for his role in demonstrating the antidepressant effects of reserpine. Subsequently, Kline was awarded a second Lasker Prize in 1964 for his contributions to psychiatry.

In this book, Healy, himself a psychiatrist, having previously published two volumes of interviews with leading psychopharmacologists, presents a fascinating story of considerable historical scholarship and amusing and interesting anecdotes. I rarely bring "technical books" with me on my vacation, but having started to read *The Antidepressant Era* before leaving, I was compelled to finish reading this story of the discovery of the antidepressants during my vacation. The complex story that Healy tells in this book not only details the discovery of the antidepressants, the emergence of the idea of depressive disease, and the evolution of psychopharmacology but also details the origins of the pharmaceutical industry and the pressures for the regulation of drug companies. Of particular interest are Healy's observations into the current efforts expended in the marketing of antidepressants. He emphasizes that pharmaceutical companies are as much in the business of selling psychotropic diagnoses as of selling psychotropic drugs.

There are two minor aspects of this book which I feel compelled to point out. A section at the end of the book lists a series of notes and references cited in the text. Many of these references are incomplete and difficult to locate. The second minor annoyance is that the structures shown for the antidepressants on pages 50, 51, 75, and 200 were carelessly drawn and in most cases are incorrect.

This book will be of interest not only to chemists, pharmacologists, and clinicians in the pharmaceutical industry and in academia but to all those interested in the history of science and the politics of scientific discovery. The book makes fascinating reading and is highly recommended.

**John L. Neumeyer**

*Alcohol and Drug Abuse Research Center  
McLean Hospital  
Harvard Medical School  
115 Mill Street  
Belmont, Massachusetts 02178*

JM980585W

10.1021/jm980585w